Rapid administration of undiluted loading doses of levetiracetam.

Autor: Martinez S; Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA., Bonnin SS; Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA., Radosevich J; Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA., Haller JT; Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Jazyk: angličtina
Zdroj: Epilepsia [Epilepsia] 2024 Mar; Vol. 65 (3), pp. 615-619. Date of Electronic Publication: 2024 Jan 16.
DOI: 10.1111/epi.17872
Abstrakt: Objective: Rapid administration of antiseizure medications is a critical concept in the treatment of status epilepticus. Although undiluted levetiracetam (LEV) doses of up to 2500 mg have been evaluated, minimal data exist to support the safety of loading doses up to 4500 mg. This study will evaluate intravenous (IV) push administration of undiluted LEV from 2500 to 4500 mg for safety outcomes as well as tolerability.
Methods: This is a retrospective, observational, cohort analysis of adult patients who received at least one loading dose of undiluted IV push LEV from October 15, 2019, to April 30, 2022, at a large academic medical center in Phoenix, Arizona. Relevant outcomes include the safety and tolerability of rapid administration of undiluted LEV at higher loading doses.
Results: We evaluated 518 loading doses in 518 unique patients included during the study period. LEV was a new medication for witnessed or suspected seizures in 80.3% of patients, with 31.2% having a documented history of epilepsy or seizure disorder. At the time of LEV administration, 52.9% of patients were on a general medicine floor, 34.3% were in the intensive care unit, and 12.7% were in the emergency department. The median loading dose of LEV was 3600 mg (3000-4000 mg), with 4000 mg being the most common loading dose given. Peripheral IV lines were documented as the only available line in 78.6% of patients for loading dose administration. No adverse events associated with LEV administration were documented.
Significance: Rapid IV administration of undiluted doses of LEV is both safe and tolerable in loading doses of 2500-4500 mg, allowing for rapid drug administration in the setting of status epilepticus.
(© 2023 International League Against Epilepsy.)
Databáze: MEDLINE
Externí odkaz: